PW MEDTECH (01358) intends to repurchase shares.

PW MEDTECH (01358) announced that the board of directors has been granted general authorization to repurchase the company's shares on the Hong Kong Stock Exchange, up to a maximum of 10% of the total number of shares issued by the company (excluding treasury shares) as of the shareholder's annual meeting on June 10, 2025, which is up to a maximum of 149 million shares. The board of directors has decided that the company will, depending on market conditions and the repurchase authorization, repurchase shares on the open market over a period of twelve months from the date of this announcement. The board of directors has appointed dedicated personnel of the company to implement the share repurchase plan based on market conditions and the repurchase authorization. The timing, price, and amount of the repurchase will be determined according to market conditions and other factors. Under the rules of the Hong Kong Stock Exchange, the actual purchase price for each repurchase shall not exceed 5% or more of the average closing price of the last five trading days prior to each repurchase. The company will provide funding for the share repurchase plan from its existing available cash.